Fmoc-Asp(OtBu)-OHCAS# 71989-14-5 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 71989-14-5 | SDF | Download SDF |
PubChem ID | 7009545 | Appearance | Powder |
Formula | C23H25NO6 | M.Wt | 411.5 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoate | ||
SMILES | CC(C)(C)OC(=O)CC(C(=O)[O-])NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 | ||
Standard InChIKey | FODJWPHPWBKDON-IBGZPJMESA-M | ||
Standard InChI | InChI=1S/C23H25NO6/c1-23(2,3)30-20(25)12-19(21(26)27)24-22(28)29-13-18-16-10-6-4-8-14(16)15-9-5-7-11-17(15)18/h4-11,18-19H,12-13H2,1-3H3,(H,24,28)(H,26,27)/p-1/t19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Fmoc-Asp(OtBu)-OH Dilution Calculator
Fmoc-Asp(OtBu)-OH Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4301 mL | 12.1507 mL | 24.3013 mL | 48.6027 mL | 60.7533 mL |
5 mM | 0.486 mL | 2.4301 mL | 4.8603 mL | 9.7205 mL | 12.1507 mL |
10 mM | 0.243 mL | 1.2151 mL | 2.4301 mL | 4.8603 mL | 6.0753 mL |
50 mM | 0.0486 mL | 0.243 mL | 0.486 mL | 0.9721 mL | 1.2151 mL |
100 mM | 0.0243 mL | 0.1215 mL | 0.243 mL | 0.486 mL | 0.6075 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-Asp(OtBu)-OH
- Artemether
Catalog No.:BCN5973
CAS No.:71963-77-4
- Leiocarposide
Catalog No.:BCC8196
CAS No.:71953-77-0
- Dihydroartemisinin
Catalog No.:BCN6264
CAS No.:71939-50-9
- Sarmentosin
Catalog No.:BCN4275
CAS No.:71933-54-5
- ProINDY
Catalog No.:BCC6350
CAS No.:719277-30-2
- S-Adenosyl-L-methionine tosylate
Catalog No.:BCN2230
CAS No.:71914-80-2
- 2-Amino-5-chlorobenzophenone
Catalog No.:BCC8535
CAS No.:719-59-5
- PHA-793887
Catalog No.:BCC2521
CAS No.:718630-59-2
- Camaldulenic acid
Catalog No.:BCN3928
CAS No.:71850-15-2
- Borrelidin
Catalog No.:BCC7964
CAS No.:7184-60-3
- Sativan
Catalog No.:BCN6815
CAS No.:71831-00-0
- Ivermectin B1a
Catalog No.:BCC9005
CAS No.:71827-03-7
- Fmoc-Asn-OH
Catalog No.:BCC3079
CAS No.:71989-16-7
- Fmoc-Glu(OtBu)-OH
Catalog No.:BCC3494
CAS No.:71989-18-9
- Fmoc-Gln-OH
Catalog No.:BCC3483
CAS No.:71989-20-3
- Fmoc-Ile-OH
Catalog No.:BCC3505
CAS No.:71989-23-6
- Fmoc-Lys(Boc)-OH
Catalog No.:BCC3516
CAS No.:71989-26-9
- Fmoc-Met-OH
Catalog No.:BCC3528
CAS No.:71989-28-1
- Fmoc-Pro-OH
Catalog No.:BCC3538
CAS No.:71989-31-6
- Fmoc-Ser(tBu)-OH
Catalog No.:BCC3544
CAS No.:71989-33-8
- Fmoc-Thr(tBu)-OH
Catalog No.:BCC3552
CAS No.:71989-35-0
- Fmoc-Tyr(tBu)-OH
Catalog No.:BCC3567
CAS No.:71989-38-3
- Fmoc-Tyr(Bzl)-OH
Catalog No.:BCC3564
CAS No.:71989-40-7
- H-Thr(tBu)-OMe.HCl
Catalog No.:BCC3107
CAS No.:71989-43-0
New t-butyl based aspartate protecting groups preventing aspartimide formation in Fmoc SPPS.[Pubmed:26077723]
J Pept Sci. 2015 Aug;21(8):680-7.
Obtaining homogenous aspartyl-containing peptides via Fmoc/tBu chemistry is often an insurmountable obstacle. A generic solution for this issue utilising an optimised side-chain protection strategy that minimises aspartimide formation would therefore be most desirable. To this end, we developed the following new derivatives: Fmoc-Asp(OEpe)-OH (Epe = 3-ethyl-3-pentyl), Fmoc-Asp(OPhp)-OH (Php = 4-n-propyl-4-heptyl) and Fmoc-Asp(OBno)-OH (Bno = 5-n-butyl-5-nonyl). We have compared their effectiveness against that of Fmoc-Asp(OtBu)-OH and Fmoc-Asp(OMpe)-OH in the well-established scorpion toxin II model peptide variants H-Val-Lys-Asp-Asn/Arg-Tyr-Ile-OH by treatments of the peptidyl resins with the Fmoc removal reagents containing piperidine and DBU at both room and elevated temperatures. The new derivatives proved to be extremely effective in minimising aspartimide by-products in each application.
Parallel high-throughput accurate mass measurement using a nine-channel multiplexed electrospray liquid chromatography ultraviolet time-of-flight mass spectrometry system.[Pubmed:12820207]
Rapid Commun Mass Spectrom. 2003;17(13):1425-32.
A nine-channel multiplexed electrospray (MUX) liquid chromatography ultraviolet time-of-flight mass spectrometry (LC/UV/TOFMS) system has been used to simultaneously measure accurate masses of eluting components from eight parallel gradient LC columns. Accuracies better than 5 and 10 ppm were achieved for 50 and 80% of samples, respectively, from a single batch analysis of ten plates (960 samples) of a Fmoc-Asp(OtBu)-OH and reserpine mixture. Combinatorial library compounds were analyzed using this parallel high-throughput system in both positive and negative modes to rigorously verify expected products and identify side products. A mass accuracy of 10 ppm root mean square (RMS) is routinely obtained for combinatorial library samples from this high-throughput accurate mass LC/MS system followed by automated data processing. This mass accuracy is critical in revealing combinatorial synthesis problems that would be missed by unit mass measurement.
The aspartimide problem in Fmoc-based SPPS. Part III.[Pubmed:15849777]
J Pept Sci. 2005 Oct;11(10):650-7.
A newly developed Fmoc-Asp derivative, Fmoc-Asp beta-(2,3,4-trimethyl-pent-3-yl) ester, has been tried in the Fmoc-based SPPS of H-Val-Lys-Asp-Xaa-Tyr-Ile-OH, a well-established peptide model for studying base-catalysed aspartimide formation. When synthesizing the hexapeptide incorporating Gly, Arg(Pbf), Asn(Mtt), Asp(OtBu) or Cys(Acm) for Xaa, considerable amounts of aspartimide-related by-products were to be expected. The Asp(3) beta-carboxy protecting group and the duration of exposure to bases were varied. By-product formation could be reduced by incorporation of the new Asp derivative more efficiently than by introducing the less bulky Asp(OMpe). Significant improvements were observed in cases of prolonged contact with piperidine or DBU. Both beta-carboxy protecting groups were superior to the standard Asp(OtBu) which was also included in this study, but the additional stabilization gained by our new protecting group was valuable especially in syntheses of long peptides or difficult sequences.
A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications.[Pubmed:24055806]
Peptides. 2013 Nov;49:145-58.
Cone snail venoms provide a largely untapped source of novel peptide drug leads. To enhance the discovery phase, a detailed comparative proteomic analysis was undertaken on milked venom from the mollusk-hunting cone snail, Conus textile, from three different geographic locations (Hawai'i, American Samoa and Australia's Great Barrier Reef). A novel milked venom conopeptide rich in post-translational modifications was discovered, characterized and named alpha-conotoxin TxIC. We assign this conopeptide to the 4/7 alpha-conotoxin family based on the peptide's sequence homology and cDNA pre-propeptide alignment. Pharmacologically, alpha-conotoxin TxIC demonstrates minimal activity on human acetylcholine receptor models (100 muM, <5% inhibition), compared to its high paralytic potency in invertebrates, PD50 = 34.2 nMol kg(-1). The non-post-translationally modified form, [Pro](2,8)[Glu](16)alpha-conotoxin TxIC, demonstrates differential selectivity for the alpha3beta2 isoform of the nicotinic acetylcholine receptor with maximal inhibition of 96% and an observed IC50 of 5.4 +/- 0.5 muM. Interestingly its comparative PD50 (3.6 muMol kg(-1)) in invertebrates was ~100 fold more than that of the native peptide. Differentiating alpha-conotoxin TxIC from other alpha-conotoxins is the high degree of post-translational modification (44% of residues). This includes the incorporation of gamma-carboxyglutamic acid, two moieties of 4-trans hydroxyproline, two disulfide bond linkages, and C-terminal amidation. These findings expand upon the known chemical diversity of alpha-conotoxins and illustrate a potential driver of toxin phyla-selectivity within Conus.
On the use of N-dicyclopropylmethyl aspartyl-glycine synthone for backbone amide protection.[Pubmed:19924731]
J Pept Sci. 2010 Jan;16(1):65-70.
To prevent aspartimide formation and related side products in Asp-Xaa, particularly Asp-Gly-containing peptides, usually the 2-hydroxy-4-methoxybenzyl (Hmb) backbone amide protection is applied for peptide synthesis according to the Fmoc-protocols. In the present study, the usefulness of the recently proposed acid-labile dicyclopropylmethyl (Dcpm) protectant was analyzed. Despite the significant steric hindrance of this bulky group, N-terminal H-(Dcpm)Gly-peptides are quantitatively acylated by potent acylating agents, and alternatively the dipeptide Fmoc-Asp(OtBu)-(Dcpm)Gly-OH derivative can be used as a building block. In contrast to the Hmb group, Dcpm is inert toward acylations, but is readily removed in the acid deprotection and resin-cleavage step.